☆ 4.5 Article

Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines

HEALTH AFFAIRS (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020

Kevin Outterson et al.

Summary: Limited accessibility of new antibacterials in high-income countries challenges the assumption that these countries have complete access to all medicines. This study reveals that many high-income countries have limited patient access to new antibacterials, even after regulatory approval.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Editorial Material Immunology

Antibacterial R&D at a Crossroads: We've Pushed as Hard as We Can... Now We Need to Start Pulling! COMMENT

John H. Rex et al.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Health Care Sciences & Services

Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States

Dzintars Gotham et al.

Summary: In response to limited pipeline of new antibacterials, France, Germany, Sweden, US, and UK have implemented reimbursement interventions such as exceptions in cost-containment mechanisms and guaranteed minimum annual revenue for selected drugs. UK and Sweden are piloting entirely novel procurement and reimbursement models, while existing interventions in US, France, and Germany are relatively minor.

HEALTH POLICY (2021)

添加到收藏夹

Article Immunology

Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe

Christine Ardal et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Review Medical Laboratory Technology

Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization

Kevin Outterson et al.

TRANSLATIONAL RESEARCH (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?

Travis B. Nielsen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Letter Biotechnology & Applied Microbiology

A shot in the arm for new antibiotics

Kevin Outterson

NATURE BIOTECHNOLOGY (2019)

添加到收藏夹

Article Health Care Sciences & Services

Factors of US Hospitals Associated with Improved Profit Margins: An Observational Study

Dan P. Ly et al.

JOURNAL OF GENERAL INTERNAL MEDICINE (2018)

添加到收藏夹

Article Ethics

Simulating Market Entry Rewards for Antibiotics Development

Christopher Okhravi et al.

JOURNAL OF LAW MEDICINE & ETHICS (2018)

添加到收藏夹

Article Health Care Sciences & Services

Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation

Adrian Towse et al.

HEALTH POLICY (2017)

添加到收藏夹

Article Infectious Diseases

Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach

John H. Rex et al.

LANCET INFECTIOUS DISEASES (2016)

添加到收藏夹

Article Health Care Sciences & Services

Repairing The Broken Market For Antibiotic Innovation

Kevin Outterson et al.

HEALTH AFFAIRS (2015)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Clinical development success rates for investigational drugs

Michael Hay et al.

NATURE BIOTECHNOLOGY (2014)

添加到收藏夹

Review Microbiology

Why is big Pharma getting out of antibacterial drug discovery?

SJ Projan

CURRENT OPINION IN MICROBIOLOGY (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.